Lymph Node Yield in Gastrointestinal Cancer Surgery With or Without Prior Neoadjuvant Therapy: Protocol for a Systematic Review and Meta-analysis.
cancer
chemotherapy
gastrointestinal cancer
lymph node harvest
lymph node yield
neoadjuvant chemotherapy
neoadjuvant radiotherapy
neoadjuvant therapy
resection
surgery
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
28 Apr 2022
28 Apr 2022
Historique:
received:
27
11
2021
accepted:
31
03
2022
revised:
31
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
Lymph node yield is the number of lymph nodes retrieved during oncological resection and histopathologically identified in the resection specimen. It is an important surrogate parameter for assessing the oncological radicality of the resection of gastrointestinal carcinomas, as well as a prognostic factor in these diseases. It remains unclear if and to what extent neoadjuvant chemotherapy, radiotherapy, or chemoradiotherapy, which have become established treatments for carcinoma of the esophagus, stomach, and rectum and are increasingly used in pancreatic carcinoma, affect the lymph node yield. This systematic review with meta-analysis is conducted with the aim of summarizing the available evidence regarding the lymph node yield, an oncological surrogate marker, in patients with gastrointestinal carcinomas undergoing surgery after neoadjuvant therapy compared to those undergoing surgery without neoadjuvant therapy. Randomized and nonrandomized studies comparing oncological resection of esophageal, stomach, pancreatic, and rectal carcinoma with and without prior neoadjuvant therapy are eligible for inclusion regardless of study design. Publications will be identified with a defined search strategy in 2 electronic databases: PubMed and Cochrane Library. The primary endpoint of the analysis is the number of lymph nodes identified in the resected specimen. Secondary endpoints include the number of harvested metastatic lymph nodes, operation time, postoperative complications, pathological TNM staging, and overall and recurrence-free survival time. Using suitable statistical methods, the endpoints between patients with and without neoadjuvant therapy, as well as in defined subgroups (neoadjuvant chemotherapy, radiotherapy, or chemoradiotherapy; and patients with esophageal, gastric, pancreatic, or rectal cancer), will be compared. The literature search and data collection started in October 2021. Results are expected to be published in mid-2022. This meta-analysis will provide the most up-to-date and complete summary of the evidence on an association between neoadjuvant therapy and lymph node yield in gastrointestinal cancer surgery. The underlying hypothesis is that neoadjuvant therapy decreases the number and size of lymph nodes through lymphocyte depletion and radiation-induced fibrosis, thus leading to a lower possible lymph node yield. The findings of the meta-analysis will show if this hypothesis is supported by evidence. PROSPERO CRD218459; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021218459. DERR1-10.2196/35243.
Sections du résumé
BACKGROUND
BACKGROUND
Lymph node yield is the number of lymph nodes retrieved during oncological resection and histopathologically identified in the resection specimen. It is an important surrogate parameter for assessing the oncological radicality of the resection of gastrointestinal carcinomas, as well as a prognostic factor in these diseases. It remains unclear if and to what extent neoadjuvant chemotherapy, radiotherapy, or chemoradiotherapy, which have become established treatments for carcinoma of the esophagus, stomach, and rectum and are increasingly used in pancreatic carcinoma, affect the lymph node yield.
OBJECTIVE
OBJECTIVE
This systematic review with meta-analysis is conducted with the aim of summarizing the available evidence regarding the lymph node yield, an oncological surrogate marker, in patients with gastrointestinal carcinomas undergoing surgery after neoadjuvant therapy compared to those undergoing surgery without neoadjuvant therapy.
METHODS
METHODS
Randomized and nonrandomized studies comparing oncological resection of esophageal, stomach, pancreatic, and rectal carcinoma with and without prior neoadjuvant therapy are eligible for inclusion regardless of study design. Publications will be identified with a defined search strategy in 2 electronic databases: PubMed and Cochrane Library. The primary endpoint of the analysis is the number of lymph nodes identified in the resected specimen. Secondary endpoints include the number of harvested metastatic lymph nodes, operation time, postoperative complications, pathological TNM staging, and overall and recurrence-free survival time. Using suitable statistical methods, the endpoints between patients with and without neoadjuvant therapy, as well as in defined subgroups (neoadjuvant chemotherapy, radiotherapy, or chemoradiotherapy; and patients with esophageal, gastric, pancreatic, or rectal cancer), will be compared.
RESULTS
RESULTS
The literature search and data collection started in October 2021. Results are expected to be published in mid-2022.
CONCLUSIONS
CONCLUSIONS
This meta-analysis will provide the most up-to-date and complete summary of the evidence on an association between neoadjuvant therapy and lymph node yield in gastrointestinal cancer surgery. The underlying hypothesis is that neoadjuvant therapy decreases the number and size of lymph nodes through lymphocyte depletion and radiation-induced fibrosis, thus leading to a lower possible lymph node yield. The findings of the meta-analysis will show if this hypothesis is supported by evidence.
TRIAL REGISTRATION
BACKGROUND
PROSPERO CRD218459; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021218459.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/35243.
Identifiants
pubmed: 35482374
pii: v11i4e35243
doi: 10.2196/35243
pmc: PMC9100374
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e35243Informations de copyright
©Ulrich Ronellenfitsch, Nika Mathis, Juliane Friedrichs, Jörg Kleeff. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 28.04.2022.
Références
Oncol Rep. 2001 Jul-Aug;8(4):909-11
pubmed: 11410808
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Dis Colon Rectum. 2017 Oct;60(10):999-1017
pubmed: 28891842
Ann Surg. 2010 Aug;252(2):336-40
pubmed: 20647928
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
JAMA. 2006 Feb 8;295(6):676-80
pubmed: 16467236
Eur J Cancer. 2017 Feb;72:84-94
pubmed: 28027520
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Front Radiat Ther Oncol. 1994;28:37-45
pubmed: 7982602
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Dis Colon Rectum. 2012 Sep;55(9):1002-7
pubmed: 22874609
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
World J Surg. 2009 Feb;33(2):340-7
pubmed: 19034566
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31
pubmed: 15667963
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275